VED Strategy18 Mar 2010 09:09
Dr Chris Blackwell, Chief Executive of Vectura, commented:
“Vectura’s strategy is to develop and commercialise products in the US. Together with Sandoz’s partnership in Europe, VR315 has the potential to be a significant new product in the DPI market. Regaining complete ownership of the VR315 US programme is in line with this strategy and offers Vectura significant financial advantages. We are confident that we have the high level of expertise required to develop and successfully commercialise inhaled products, and with a robust balance sheet, we believe we have the ability to gain an enlarged share of a major market opportunity.”